Specific inhibition of Trypanosoma cruzi neuraminidase by the human plasma glycoprotein "cruzin"

Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids

Chagas disease is caused by the protozoan Trypanosoma cruzi and is endemic to Central and South America. However, it has spread around the world and affects several million people. Treatment with currently available drugs cause several side effects and require long treatment times to eliminate the parasite, however, this does not improve the chronic effects of the disease such as cardiomyopathy. A therapeutic vaccine for Chagas disease may be able to prevent the disease and improve the chronic effects such as cardiomyopathy. This vaccine would be beneficial for both infected people and those which are at risk in endemic and non-endemic areas. In this article, we will review the surface antigens of T. cruzi, in order to choose those that are most antigenic and least variable, to design effective vaccines against the etiological agent of Chagas disease. Also, we discuss aspects of the design of nucleic acid-based vaccines, which have been developed and proven to be effective against the SARS-CoV-2 virus. The role of co-adjuvants and delivery carriers is also discussed. We present an example of a chimeric trivalent vaccine, based on experimental work, which can be used to design a vaccine against Chagas disease.

Trypanosoma cruzi infection and host lipid metabolism

Trypanosoma cruzi is the causative agent of Chagas disease. Approximately 8 million people are thought to be affected worldwide. Several players in host lipid metabolism have been implicated in T. cruzi-host interactions in recent research, including macrophages, adipocytes, low density lipoprotein (LDL), low density lipoprotein receptor (LDLR), and high density lipoprotein (HDL). All of these factors are required to maintain host lipid homeostasis and are intricately connected via several metabolic pathways. We reviewed the interaction of T. cruzi with each of the relevant host components, in order to further understand the roles of host lipid metabolism in T. cruzi infection. This review sheds light on the potential impact of T. cruzi infection on the status of host lipid homeostasis.

Characterization of carbohydrate binding proteins in Trypanosoma cruzi

Trypanosoma cruzi is an obligatory intracellular protozoan parasite that causes Chagas' disease in humans and invades a great variety of mammalian cells. The nature of the ligand(s) and receptor components in both T. cruzi and target cells remains controversial, although it seems to involve an interaction with oligosaccharides. In an attempt to identify possible ligands on the parasite, we have searched for the presence of carbohydrate binding proteins (CBPs) in T. cruzi. By fluorescence-activated cell sorter analysis using a panel of fluoresceinated glyco- and neoglycopeptides with well characterized glycans, the presence of at least two different CBPs was identified on the surface of T. cruzi epimastigotes and trypomastigotes. The specificity of binding of the two CBPs seems to be mediated by galactose and mannose residues. The mannose- and galactose-mediated CBPs from epimastigotes and trypomastigotes were purified to homogeneity by affinity chromatography on immobilized thyroglobulin and identified as 60-70-kDa glycoproteins. Purified CBPs were able to specifically bind with high affinity to murine and human macrophages as well as other cell types susceptible to infection by T. cruzi but not to fat or neuronal cells. This binding was inhibited by the corresponding ligands. Moreover, the mannose-mediated CBP binding was completely abolished by alpha-mannosidase treatment of the cells. These results suggest a possible role for the CBPs in the recognition events between the parasite and target cells and/or in the interaction of the epimastigotes with the insect gut cells.

On the interaction of Trypanosoma cruzi neuraminidase and human lipoproteins

Binding and penetration of Trypanosoma cruzi to host cells is a process that preludes infection and is mediated by specific recognition molecules. Neuraminidase is one of the parasite molecules involved in infection and, in this review, we describe some of its biochemical characteristics, its interaction with human lipoproteins and its effect on infection of mammalian cells.

Similarity of cruzin, an inhibitor of Trypanosoma cruzi neuraminidase, to high-density lipoprotein

A specific inhibitor of the neuraminidase of the protozoan parasite Trypanosoma cruzi was isolated recently and named cruzin. It is now shown that cruzin is similar to high-density lipoprotein by amino acid homology, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, by immunoblot analysis, and by isoelectric focusing. Cruzin purified by ion exchange chromatography and high-density lipoprotein isolated by density gradient ultracentrifugation inhibited Trypanosoma cruzi neuraminidase to the same extent. Cruzin or high-density lipoprotein restores to normal the decreased multiplication rate of Trypanosoma cruzi epimastigotes grown in a medium depleted of lipoproteins, suggesting that it may be important for survival of the parasite in nature.